Axsome Therapeutics (AXSM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Axsome Therapeutics (AXSM)

AXSM 153.85

-0.2%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	7/26/2017 8:17:15 AM
	of 32

Ladenburg Thalmann raised its price target on Axsome Therapeutics (NASDAQ: AXSM) to $31.00 (from $28.00) while maintaining a Buy rating. July 26, 2017 6:48 AM EDT streetinsider.com Analyst Matt Kaplan comments "Interim Phase 3 data for CRPS is expected in 4Q17, with AXS-02 potentially being initially launched in the US in 2019, and other indications following in later years. We estimate AXS-02 can achieve $150 million in revenue in CRPS, with other pain indications also adding materially. At peak, we estimate AXS-02 can reach $600 million."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next